Literature DB >> 10700481

Use of oral corticosteroids in the United Kingdom.

T P van Staa1, H G Leufkens, L Abenhaim, B Begaud, B Zhang, C Cooper.   

Abstract

Administration of oral corticosteroids is associated with the development of osteoporosis and an increased risk of fractures. However, the size of the treated sub-population who would benefit from preventive therapy remains uncertain. The objective of this study was to investigate the usage pattern of oral corticosteroids in a large sample representative of the general population in England and Wales. Information was obtained from the General Practice Research Database (GPRD) which contains medical records of general practitioners. Oral corticosteroid users were patients aged 18 years or older who received one or more prescriptions for oral corticosteroids. Over 1.6 million oral corticosteroid prescriptions were issued to the cohort of 244 235 oral corticosteroid users. At any point in time, oral corticosteroids were being used by 0.9% of the total adult GPRD population. The highest use (2.5%) was by people between 70 and 79 years of age. Respiratory disease was the most frequently recorded indication for oral corticosteroid treatment (40%). Patients with arthropathies were most likely to use long-term, continuous treatment, and patients with chronic obstructive pulmonary disease least likely (19.3% and 6.1%, respectively, used oral corticosteroids for more than 2 years). The overall use of bone-active medication (oestrogens, bisphosphonates, vitamin D, and calcitonin) during oral corticosteroid treatment was low (between 4.0% and 5.5%). The current population in the UK at risk of developing corticosteroid-induced fractures might be as large as 350 000. Identification of these patients will be important for implementing preventive strategies in a cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10700481     DOI: 10.1093/qjmed/93.2.105

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  138 in total

1.  Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.

Authors:  S Censi; J Manso; G Pandolfo; G Franceschet; E Cavedon; Y H Zhu; S Carducci; W Gomiero; M Plebani; M Zaninotto; S Watutantrige-Fernando; C Mian; V Camozzi
Journal:  J Endocrinol Invest       Date:  2018-12-05       Impact factor: 4.256

2.  Upregulation of nucleoside triphosphate diphosphohydrolase-1 and ecto-5'-nucleotidase in rat hippocampus after repeated low-dose dexamethasone administration.

Authors:  Dunja Drakulić; Miloš Stanojlović; Nadežda Nedeljković; Ivana Grković; Nataša Veličković; Ivana Guševac; Nataša Mitrović; Ivana Buzadžić; Anica Horvat
Journal:  J Mol Neurosci       Date:  2014-11-01       Impact factor: 3.444

3.  Current management of corticosteroid-induced osteoporosis: variations in awareness and management.

Authors:  J G Ryan; R K Morgan; P J Lavin; F E Murray; P G O'Connell
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

Review 4.  Diagnosis and treatment of ACTH deficiency.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 5.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

6.  Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group.

Authors:  Jonathan T L Cheah; Rachel J Black; Joanna C Robson; Iris Y Navarro-Millán; Sarah R Young; Pamela Richards; Susan Beard; Lee S Simon; Susan M Goodman; Sarah L Mackie; Catherine L Hill
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

7.  An unusual case of hypercortisolism with multiple weight-bearing bone fractures.

Authors:  Georgios Papadakis; Brigitte Uebelhart; Michel Goumaz; Sophie Zawadynski; Rene Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

8.  Glucocorticoid-induced osteoporosis: how best to avoid fractures.

Authors:  Mark S Cooper
Journal:  Ther Adv Chronic Dis       Date:  2010-01       Impact factor: 5.091

Review 9.  Conference summary and conclusions. A comprehensive approach to predicting and managing mood effects of glucocorticoids.

Authors:  Esther M Sternberg; Lewis L Judd
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.

Authors:  P C Souverein; A Berard; T P Van Staa; C Cooper; A C G Egberts; H G M Leufkens; B R Walker
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.